Neocrin Co.: The Irvine biomedical company said...

Neocrin Co.: The Irvine biomedical company said Monday that it has raised $12.5 million in a self-managed private offering, selling about 2.5 million series C preferred shares. The company said previous investors bought about half the offering, and new investors led by Hancock Venture Partners bought the remaining shares.